Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
3 results loaded, newest first. End of these results.
Estrella Immunopharma reported encouraging initial tolerability in the first patient receiving two EB103 infusions in STARLIGHT-1’s dose-expansion phase for relapsed/refractory B-cell non-Hodgkin’s lymphoma. The patient received infusions three weeks apart, with no treatment-related serious adverse events reported duri
For best results when printing this announcement, please click on link below: Estrella Immunopharma Treats First Patient with Two EB103 Infusions in STARLIGHT-1 Dose-Expansion Phase Patient received two infusions three weeks apart at the recommended Phase II dose; no treatment-related serious adverse events observed th
The patient received two EB103 infusions.